TMIGD2 expression has been found to be significantly upregulated in glioma patients, correlating with better overall survival and increased immune cell infiltration, and is negatively associated with pathways such as angiogenesis and hypoxia, suggesting its role in inhibiting tumor progression (Boulhen et al. 2023). This evidence concerns the gene TMIGD2 and central nervous system cancer.